BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents
- 1 August 2007
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 12 (2), 171-185
- https://doi.org/10.1016/j.ccr.2007.07.001
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or BakScience, 2007
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- An Mll-Dependent Hox Program Drives Hematopoietic Progenitor ExpansionCurrent Biology, 2004
- Cell DeathCell, 2004
- BAX and BAK Regulation of Endoplasmic Reticulum Ca 2+ : A Control Point for ApoptosisScience, 2003
- BH3 domains as BCL-2 inhibitors: prototype cancer therapeuticsExpert Opinion on Biological Therapy, 2003
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001
- Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of ApoptosisScience, 1997
- Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18Cell, 1985